Latest from Stock takes

Stock Takes: Infant formula recall gives investors jitters, Colonial's upgrade and BlackRock still bullish

Synlait Milk says none of its ingredients are linked to the overseas recall.

Stock Takes: BlackRock still 'pro-risk' despite talk of AI bubble

BlackRock's unrelenting 'pro-risk' approach, and Vital management goes internal.

Stock Takes: Falling interest rates could push investors back to high-dividend shares

Dividend stocks like Sky TV and Spark now offer yields of 10% or more.

Stock Takes: Can the a2 Milk leopard change its spots?

Dual-listed a2 Milk is becoming an infant formula manufacturer in its own right.

Stock Takes: Could F&P Healthcare surprise with better than forecast result?

F&P Healthcare has forecast revenue of $1.075b and net profit of $200m for the half.

Stock Takes: Ebos faces tougher path after post-result downgrades

Ebos shares have slumped 29% since hitting a peak of $41.25 on August 21.

Stock Takes: UDC makes solid profit but credit losses climb

The company booked a credit impairment charge of $39.8m in the 15 months to March 31.

Stock takes: NZ economic recovery – are we there yet?

What the latest company reporting season tells us about the state of the economy.